Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles. First approved in October 2017 by the Food and... First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as first line therapy.
- Mechanism
- Curator reviewed · 2 references
Shingrix provides protection against Herpes Zoster reactivation by eliciting an immune response to Varicella Zoster Virus (VZV). The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). Immune exposure to gE protein stimulates the development of anti-gE antibodies, and therefore adaptive immunity to VZV. The adjuvant system, AS01B, is also included in Shingrix to enhance the immunological response to the vaccine leading to longer lasting and greater immunogenicity to the herpes zoster virus.
- Primary indication
- Varicella zoster vaccine is indicated for the prevention of herpes zoster (HZ) (shingles) in adults aged 50 years and older and in adults aged 18 years and older who are or will be at increased...Curator reviewed · 3 structured indications
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2021
- Also known as
- gE recombinant Varicella zoster virus (VZV) glycoprotein E · gE: Recombinant Varicella Zoster Virus (VZV) glycoprotein E · Recombinant Varicella zoster virus (VZV) glycoprotein E · Recombinant varicella zoster virus glycoprotein E antigen
- Code names
- GSK-1437173A
- Brand names
Resolves to
What you can answer from here — as of July 21, 2026
Which other approved drugs treat the same conditions as Varicella zoster vaccine (recombinant), and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account